Research Article

mRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer

Peixin Chen,1,2 Shengyu Wu,1,2 Jia Yu,1,2 Xuzhen Tang,3 Chunlei Dai,3 Hui Qi,3 Junjie Zhu,4 Wei Li,1,2 Bin Chen,1,2 Jun Zhu,1,2 Hao Wang,1,2 Sha Zhao,1,2 Hongcheng Liu,4 Peng Kuang,5 and Yayi He1,2

1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China
2Medical School, Tongji University, Shanghai 200433, China
3Oncology and Immunology BU, Research Service Division, WuXi AppTec, Shanghai, China
4Department of Surgery, Shanghai Pulmonary Hospital, Tongji University, Tongji University School of Medicine, Shanghai 200433, China
5Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Correspondence should be addressed to Hongcheng Liu; lhcsz@163.com, Peng Kuang; 18811792676@163.com, and Yayi He; yayi.he@tongji.edu.cn

Received 24 May 2021; Revised 14 June 2021; Accepted 5 August 2021; Published 28 September 2021

Academic Editor: Osamah Ibrahim Khalaf

Copyright © 2021 Peixin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Small-cell lung cancer (SCLC) has poor prognosis and is prone to drug resistance. It is necessary to search for possible influencing factors for SCLC chemotherapy insensitivity. Therefore, we proposed an mRNA network to track the chemotherapy insensitivity in SCLC. Methods. Six samples of patients with SCLC were recruited for RNA sequencing. TopHat2 and Cufflinks were used to make differential analysis. Functional analysis was applied as well. Finally, multidimensional validation was applied for verifying the results we obtained by experiment. Results. This study was a trial of drug resistance in 6 SCLC patients after first-line chemotherapy. The top 10 downregulated genes differentially expressed in the chemo-insensitive group were SERPING1, DRD5, PARVG, PRAME, NKX1-1, MCTP2, PID1, PLEKHA4, SPP1, and SLN. Cell-cell signaling by Wnt (p = 6.98E−21) was the most significantly enriched GO term in biological process, while systemic lupus erythematosus (p = 6.97E−10), alcoholism (p = 1.01E−09), and transcriptional misregulation in cancer (p = 0.00227988) were the top three ones of KEGG pathways. In multiple public databases, we also highlighted and verified the vital role of glycolysis/gluconeogenesis pathway and corresponding genes in chemo-insensitivity in SCLC. Conclusion. Our study confirmed some SCLC chemotherapy insensitivity-related genes, biological processes, and pathways, thus constructing the chemotherapy-insensitive network for SCLC.

1. Introduction

Small-cell lung cancer (SCLC), as a kind of neuroendocrine tumor, remains one of the most deadly cancers [1]. Surgery for SCLC is limited to very early stages [2]. Chemotherapy is the first-line and second-line standard treatment for SCLC [3]. Etoposide/cisplatin (EP) [4] and etoposide/carboplatin (EC) [5] were clinically used for limited disease (LD) SCLC and extensive disease (ED) SCLC. Cisplatin/irinotecan was applied for LD-SCLC (JCOG0202) [6]. Topotecan [7], irinotecan [8], gemcitabine [9], and many others are often chosen for relapsed or refractory SCLC. For patients with SCLC, there are some clinical trials to investigate more effective combination therapy regimens. For example, the TORG 0604 trail illustrated the efficacy and safety of carboplatin combined with irinotecan and sequential thoracic radiotherapy (TRT) for patients with LD-SCLC [10]. For patients with ED-SCLC, the ECOG-ACRIN 2511 study aimed to evaluate the efficacy of EP combined with veliparib or placebo [11]. Nevertheless, there are still some SCLC
patients insensitive to chemotherapy, which affect the clinical prognosis seriously [12, 13]. In the CONVERT trial, circulating tumor cells were used for efficacy evaluation and prognosis prediction [14]. However, the mechanisms of chemotherapy resistance in SCLC are complex [13, 15]. As a result, it is necessary to search for more possible influencing factors for SCLC chemotherapy insensitivity.

Messenger RNA (mRNA) is transcribed from DNA and carries the corresponding genetic information to provide the necessary information for the next translation into protein [16]. Previous studies have suggested strong association with mRNAs and drug resistance based on RNA sequencing (RNA-Seq). For instance, paclitaxel resistance is correlated with ABCB1 mRNA expression [17]. Other mRNAs such as FBXW7 were documented to be resistant to gefitinib and promoted tumor development [18]. Therefore, we proposed that mRNAs play a role in SCLC chemotherapy insensitivity.

This study set out to construct the mRNA network of chemotherapy insensitivity in SCLC. We considered the reasons of drug insensitivity from four aspects: the genes, the biological process, the KEGG pathways, and mutations of drug targets. Based on RNA-Seq and differential analysis, the upregulated and downregulated genes were identified. After that, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. We also did multidimensional validation to explore the hypothesis in view of the experiment.

To our knowledge, this study proposed a new direction of chemical resistance in SCLC. Some genes and pathways which have never revealed their function before were shown in our study. It thus provides new strategies for treatment henceforth. Importantly, multiple public databases were fully used to further verify the results we obtained by experiment.

2. Methods

2.1. Data Acquisition. After recruiting patients by lung biopsy for diagnosis from October 2018 to February 2019 in Shanghai Pulmonary Hospital, 6 male SCLC patients remained finally. All of them signed informed consent. The experimental protocol acquired Shanghai Pulmonary Hospital Ethics Committee permission [19].

2.2. RNA-Seq Analysis. Prior to sequencing library, total RNA needed to be extracted right after the section was diagnosed as SCLC by pathologists. It was extracted from fresh frozen SCLC tissues with an RNeasy 96 Universal Tissue Kit (Qiagen, Gaithersburg, MD, USA). After RNA isolation, the extraction effect was detected by agarose gel electrophoresis (Thermo Scientific, Bioanalyzer 2100; Agilent Technologies, USA). A Nano-Drop spectrophotometer (Nano-Drop 1000 Spectrometer) was next used to determine the quality and concentration of the total RNA (1.7 < OD260/OD280 < 2.0).

The next step in this process was construction of sequencing library. The double-stranded cDNA was synthesized by reverse transcription reaction, which added “A” in the 3’ end (Illumina, San Diego, CA, USA). Following this process, Illumina TruSeq RNA was constructed.

Following the use of electrophoresis to extract double-stranded cDNA fragment, suitable fragments were isolated. Then, DNA cluster amplification was carried out by quantitative polymerase chain reaction. The DNA amplicons were linearized into a single strand. Finally, high-throughput RNA-Seq was performed using the Illumina HiSeqTM 2000 platform [19].

2.3. Utility of Differential Analysis. TopHat2 [20] and Cufflinks [21] were used to analyze RNA-Seq data. RNA-Seq reads were mapped to the reference genome by TopHat2. Afterwards, multiple sequence alignment and transcriptional abundances were performed by Cufflinks. Therefore, differentially expressed genes (DEGs) could be identified.

Based on Cufflinks package (Cufflinks, Cuffmerge, Cuffcompare, and Cuffdiff), transcripts were assembled. Then, transcript assemblies were compared to annotation and merged. Finally, DEGs were found. We chose mean fold change (FC) as the gene expression relative abundance. On completion of analysis in Cufflinks package, the paired t-test was executed for significant difference analysis in different groups.

2.4. Functional and Pathway Enrichment Analyses. Functional enrichment analysis like GO [22–24] and pathway enrichment analysis such as KEGG enrichment analysis [25, 26] were employed. R version 2.15.1 (http://www.r-project.org.) was utilized for differential gene visualization. $p \geq 0.05$ was not statistically significant.

2.5. Multidimensional Validation. In support of our experimental result, multidimensional validation was employed for minimizing bias. AmiGo2 software was selected for further GO analysis (http://amigo.geneontology.org/amigo/landing.). KEGG Pathway database [27] was in use for verifying significantly enriched pathways in this study. Pathway Card [28] was then applied for the main genes in the KEGG pathway. The effect of those main genes was discussed in some public databases from tissues (The Genotype-Tissue Expression (GTEx) [29], PROGeneV2 [30], cBiportal [31], and The Human Protein Atlas [32]), cells (Cancer Cell Line Encyclopedia (CCLE) [33] and Oncomine [34]), and molecules (Metascape [35] and String [36]) (Figure 1).

All the processes are shown in Figure 2.

3. Results

3.1. Clinical Characteristics of SCLC Patients. This study was a trial of drug resistance in 6 SCLC patients after first-line chemotherapy. The average age was 64.2. All these patients were males and smokers. Two of them were LD-SCLC, and the rest were in the stage of ED. Among them, four patients had tumor metastasis while two did not. Only one of them received the treatment plan as EP. Others adopted EC. One
half of them were identified as partial response (PR), and the other half were progressive disease (PD) or stable disease (SD) [19].

3.2. Features of RNA-Seq Results. We chose total throughput, counted reads, left processed, right processed, and total mapped features as key points of analysis in RNA-Seq. All these data were not apparently different between the PR group and the SD + PD group. Table 1 provides an overview of RNA-Seq features in two groups.

3.3. Differentially Expressed mRNAs. Based on R software, we analyzed all data and selected the DEGs. We also identified the absolute value of FC $> 2$ and $p$ value by the paired $t$-test less than 0.05 as the criterion for differentially expressed mRNAs. The top 10 downregulated genes differentially expressed in chemo-insensitive (SD or PD) tissues compared to those in chemo-sensitive (PR) tissues were SERPING1, DRD5, PARVG, PRAME, NKX1-1, MCTP2, PID1, PLEKHA4, SPP1, and SLN (Table 2), whereas AC008763.3, DBX2, ZIC1, CHRM3, ZNF541, AGBL1, TNNI2, MTUS2, CCDC36, and STAG3 were the top 10 upregulated DEGs (Table 3).

3.4. GO Categories and KEGG Pathways. Three GO categories were applied for the PR and SD + PD groups in this research: cellular component (CC), biological process (BP), and molecular function (MF). The bar chart presented the count and description of the three GO functions (Figure 3). What stands out in CC was the axon part (GO: 0033267, $p = 2.42E - 25$). The column height implied the number of genes in each term. After GO enrichment analysis, the
way-related genes were demonstrated from Pathway Card pathway (Figure S2). The glucose/gluconeogenesis pathway [37] was applied for the glycolysis/gluconeogenesis pathway might play a nonnegligible role in cancer (hsa05202, p = 6.97E−21). Other enriched GO-BP functions identified were Wnt signaling pathway (GO: 0016055, p = 1.18E−20), Ras protein signal transduction (GO: 0007265, p = 1.83E−20), and other terms.

DMGs were assigned to KEGG pathways as well. The count of genes in each description can be clearly seen in Table 4. The top 3 enriched KEGG pathways were systemic lupus erythematosus (hsa05322, p = 6.97E−10), alcoholism (hsa05034, p = 1.01E−09), and transcriptional misregulation in cancer (hsa05202, p = 0.0227988) (Table 5).

3.5. Multidimensional Validation. We chose AmiGo2 software to find the association between meaningful GO terms mentioned above. Except for two GO terms (GO: 0009892 and GO: 0033267), extensive interaction was found among enrolled GO terms and other GO terms. In the whole database, the location of top 10 GO terms mentioned in Table 4 was illustrated (Figure S1).

Considering the vital role of metabolism in cancer development, progression, and metastasis, on the basis of KEGG results, we put forward a hypothesis that the glycolysis/gluconeogenesis pathway might play a nonnegligible role in SCLC. To verify our hypothesis, firstly, KEGG Pathway database [37] was applied for the glycolysis/gluconeogenesis pathway (Figure S2). Then, glycolysis/gluconeogenesis pathway-related genes were demonstrated from Pathway Card [38]. Phosphoglycerate mutase 2 (PGAM2), phosphoglycerate kinase 1 (PGK1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), triosephosphate isomerase 1 (TPI1), and pyruvate kinase M1/2 (PKM) were the representative genes of the glycolysis/gluconeogenesis pathway. Subsequently, some databases were used for verifying the role of the pathway from three levels: tissue, cell, and molecule, for instance, GTEx (tissue) (Figure S3), PROGgeneV2 (tissue) (Figure S4), cBioportal (tissue) (Figures S5–S11), The Human Protein Atlas (tissue), CCLE (cell) (Figure S12), Oncomine (cell) (Figure S13), Metascape (molecule) (Figure S14), and String (molecule) (Figure S15). All of the details can be found in Tables S1 and S2. The expressions of PGAM2, PKG1, GAPDH, TPI1, and PKM were found in tumor tissues or cell lines (Figures S3–S15). In Figure S4, high GAPDH expression was linked to shorter overall survival (OS) in lung cancer (p = 0.009812). In the cBioportal dataset, the survival analysis suggested that PKM mutation indicated poor prognosis (p = 0.012, Figure S5). However, the sample size of the PKM mutation group was too small to fully reflect the relationship between mutation status of PKM and prognosis. Importantly, PGK1, GAPDH, and TPI1 were not mutated in tumor tissues as seen from the cBioportal dataset (Figure S5). In addition, in the cBioportal cohort with 81 clinical SCLC patients who owned RNA-Seq data, we explored the relationship between expression levels of main genes in the glycolysis/gluconeogenesis pathway and OS. As shown in Figure S6, high PKM expression was correlated with better prognosis (p < 0.0001). Then, the correlation between gene expression level and clinicopathologic features, including age, gender, smoking history, metastasis, and TNM staging, were estimated (Figures S7–S11). Overexpression of GAPDH, PGAM2, PKG1, and PKM was found in patients over the age of 65. In comparison with female patients, male patients with SCLC showed higher expression of PGAM2 and PGK1. GAPDH, PGAM2, PKG1, and PKM were also highly expressed in SCLC tissues from smokers. However, no significant results were found between gene expression and clinicopathologic features (both p > 0.05). The extensive connection among vital genes of the glycolysis/gluconeogenesis pathway was found (Figures S14 and S15). Overall, these multidimensional validations supported the view that the abnormal glycolysis/gluconeogenesis pathway had something to do with the chemotherapy insensitivity in SCLC.
In short, the network of DEGs in PR and SD + PD groups was constructed. Upregulated and downregulated DEGs in the PR group were found. DEGs-related GO terms and KEGG signaling pathways were also illustrated. Finally, scientific hypothesis was produced as follows: the chemotherapy insensitivity in SCLC was related to KEGG signaling pathways and GO terms, such as systemic lupus erythematosus, glycolysis/gluconeogenesis pathway, and cell-cell signaling by Wnt.

### 4. Discussion

Despite various treatments, systemic chemotherapy is still the main treatment for SCLC [39]. There are several clinical trials as well. For example, ipilimumab or placebo plus etoposide and platinum were used for efficacy and safety in ED-SCLC patients [40]. TORG 0604 was aimed at evaluating the effect of carboplatin combined with
irinotecan and TRT in LD-SCLC [10]. In our study, EP and EC were supplied to these patients, respectively. The function of them was published in the JCOG 9702 trial. It revealed the curative effect in the elderly. EP was the traditional treatment and EC could be another alternative due to the similar palliative scores [41]. In recent years, much attention is paid to metronomic chemotherapy. Weekly paclitaxel is workable as a second-line treatment for recurrent SCLC [42]. However, the drug resistance of SCLC is inevitable although it is initially sensitive to chemotherapy [12, 13, 43]. With high recurrence rate, the exploration of factors for SCLC chemotherapy insensitivity is essential.

We proposed genes play a role in chemotherapy insensitivity. Previous studies have mentioned genes like MRP, MDR1 [44], EZH2 [45], and many others. In this paper, we identified the DEGs between PR and SD + PD group through RNA-Seq. It can sort, classify, and compare gene expression [46]. By detecting the transcription of mRNA, our study proved the downregulation of SPP1 was associated with chemotherapy resistance in SCLC, which was consistent with previous studies [47]. Recently, through in vivo and in vitro experiments, Tang et al. found that SPP1 induced non-small-cell lung cancer (NSCLC) progression and cisplatin resistance [48]. By RNA-Seq and differential analysis, we also found the correlation between downregulated genes like DRD5, PRAME, and SERPING1 and chemotherapy insensitivity. DRD5, which is associated with receptor-related signal transduction on cell surface [49], can inhibit tumor growth by promoting autophagic cell death [50]. There has been a considerable amount of investigation into PRAME. Expression of PRAME was correlated with tumor histology and smoking status [51]. It played an important role in the invasion [52] and metastasis [53] of lung cancer. For cancer patients, overexpression of PRAME was frequently correlated with poor prognosis [54, 55]. Furthermore, the low expression of SERPING1 represented poor prognosis in prostate cancer [56]. All these results suggested they were often downregulated in tumors and the downregulation led to tumor development and metastasis. However, there is limited report on their roles in drug resistance at present.
This is what we need to further study in the future. STAG3 and CHRM3 upregulated in our research can be viewed as chemotherapy-resistance-associated tumor genes. Mutations in STAG3 are usually associated with premature ovarian failure [57]. Downregulating the expression of STAG3 decreased the sensitivity of BRAF-mutant melanoma cells to inhibitors of BRAF [58]. CHRM3 seemed to be upregulated in gastric cancer patients who were responsive to ramucirumab [59]. Although they play the role of drug resistance in some cancers, there is still no clear evidence to demonstrate their relevant function in SCLC currently. Therefore, more researches are essential to clarify whether STAG3 and CHRM3 cause chemotherapy insensitivity in SCLC.

Functional and pathway enrichment analyses were also employed in our research. Based on GO and KEGG analysis, for PR and SD+PD groups, biological characteristics of genes and the relationship between gene regulatory networks and gene function were discovered [60]. After GO analysis, we knew different activities in cells. In this case, SCLC chemotherapy insensitivity was mainly connected with cell-cell signaling by Wnt, Wnt signaling pathway, and Ras protein signal transduction on the cellular level. Afterwards, AmiGo2 software was applied for the associated genes in GO terms mentioned above and the location of GO terms in the whole database. Systemic lupus erythematosus, a KEGG pathway, was proved to be downregulated in the PR group. In recent years, mRNAs have been considered to be closely related to autoimmunity diseases [61]. Evidence showed the hierarchical association of systemic lupus erythematosus and various types of cancer, including lung cancer [62–65]. It was driven by gene region 6p21-22 and is strongly associated with lung cancer. However, this was correlated with squamous cell lung carcinoma [66]. Alcoholism was another significantly downregulated pathway in the PR group. Systemic lupus erythematosus and alcoholism also played a role in mitoxantrone insensitivity in NSCLC [67]. The related studies in SCLC are not sufficient at present. Our team has confirmed the two pathways above after analysis of long noncoding RNAs and microRNAs previously [19]. The same result in mRNA was proved this time.

Moreover, we found the aberrant glycolysis/gluconeogenesis KEGG pathway in SCLC chemotherapy resistance. With a p value less than 0.05, it was one of the significant pathways in our study. It belongs to pathway network for glucose metabolism, SuperPath [68, 69]. Just like any other type of cancer, SCLC cells use aerobic glycolysis as the main source of adenosine triphosphate [70]. Notably, higher total lesion glycolysis (TLG) is correlated with poorer prognosis of SCLC [71]. A-disintegrin-and-metalloprotease 12-s (Adam12S), a protein related to tissue growth and development, promoted SCLC cell proliferation, migration, and invasion by upregulating the rate-limiting enzyme hexokinase 1 in glycolysis [72]. Reducing glycolysis can promote tumor invasion by SCLC cell population [73]. Monocarboxylate transporter 1 (MCT1) inhibitor called AZD3965 killed those glycolysis-dependent tumor cells through lactate transport regulation, especially in SCLC patients with tumor expression of MCT1 and lack of MCT4 [74]. Currently, the dependence of cancer cells on energy production by glycolysis has been well studied. There are also some research on the function of glycolysis and gluconeogenesis in chemotherapy insensitivity. Drug-resistant cancer cells showed higher glycolysis. Emerging evidence points to the abnormal glucose metabolism causing resistance to cancer therapy [75, 76]. And, targeting glycolysis pathway was considered as a new strategy to overcome drug resistance [77, 78]. The altered glycolysis may be connected with stem cell-like cancer [72]. Cancer stem cells were a kind of monoenergetic cell group existing in the tumor cell group and highly resistant to chemotherapeutic drugs [75]. In pancreatic cancer, L-type amino acid transporter 2 (LAT2) promoted glycolysis and reduced gemcitabine sensitivity by regulating glutamine-dependent mTOR [79]. Overexpression of FGFR4 can increase glucose metabolism and result in breast cancer chemical resistance [80]. In lung cancer, another important discovery was found. Hepatocyte growth factor (HGF) regulation by secreted lactate was the adaptive resistance that led to continuous resistance to tyrosine kinase inhibitors [81]. Although there has been substantial research on the mechanisms of cancer chemotherapy insensitivity, few are about gluconeogenesis. The mechanisms in SCLC also remain to be confirmed. To further verify the result of the abnormal glycolysis/gluconeogenesis pathway in SCLC chemical resistance by KEGG analysis, multidimensional validation was performed. We chose Pathway Card for the top five genes in the glycolysis/gluconeogenesis pathway. Then, we put them into some public databases to verify the pathway function. The result was the same as that in KEGG analysis.

Although these studies revealed important findings, they also had limitations. The findings were required to be carried out as in vivo and in vitro experiments. This is what we will do next. Furthermore, we must mention that the small sample size might have a certain impact on the result. A large number of patients with SCLC need to be investigated in the future.

5. Conclusion

Our study confirmed that genes such as SERPING1, DRD5, and PARVG were involved in SCLC chemotherapy response by complex biological processes. Pathways such as systemic lupus erythematosus, alcoholism, and glycolysis/gluconeogenesis were also involved.

Abbreviations

| Abbreviation | Description                                        |
|--------------|----------------------------------------------------|
| SCLC:        | Small-cell lung cancer                             |
| mRNA:        | Messenger RNA                                      |
| GO:          | Gene Ontology                                      |
| KEGG:        | Kyoto Encyclopedia of Genes and Genomes           |
| GTEx:        | The Genotype-Tissue Expression                     |
| CCLE:        | Cancer Cell Line Encyclopedia                      |
| LD:          | Limited disease                                    |
| ED:          | Extensive disease                                  |
| EP:          | Etoposide plus cisplatin                           |
| EC:          | Etoposide plus carboplatin                          |
| PR:          | Partial response                                   |
Table S1: multidimensional external validation results based on multiple databases.

Table S2: summary of multidimensional external validation results based on multiple databases.

**Data Availability**

The shared sequencing data can be obtained from the corresponding author upon request via email (yayi.he@tongji.edu.cn) for clinical and practical reasons.

**Disclosure**

Peixin Chen, Shengyu Wu, and Jia Yu are the first authors.

**Conflicts of Interest**

The authors declare that there are no conflicts of interest.

**Acknowledgments**

This study was supported in part by a grant of the National Natural Science Foundation of China (81802255), Clinical Research Project of Shanghai Pulmonary Hospital (FKLY20010), Young Talents in Shanghai (2019 QNBJ), “Dream Tutor” Outstanding Young Talents Program (fkcx1901), Clinical Research Project of Shanghai Pulmonary Hospital (FKLY20001), Respiratory Medicine, a Key Clinical Specialty Construction Project in Shanghai, Promotion and Application of Multidisciplinary Collaboration System for Pulmonary Non Infectious Diseases, Clinical Research Project of Shanghai Pulmonary Hospital (fk18005), Key Discipline in 2019 (Oncology), Project of Shanghai Municipal Science and Technology Commission (Project of Municipal Science and Technology Commission), Scientific Research Project of Shanghai Pulmonary Hospital (fkcx1903), Shanghai Municipal Commission of Health and Family Planning (2017YQ050), Innovation Training Project of SITP of Tongji University, Key Projects of Leading Talent (19411950300), and Youth Project of Hospital Management Research Fund of Shanghai Hospital Association (Q1902037).

**Supplementary Materials**

Table S1: multidimensional external validation results based on multiple databases. Table S2: summary of multidimensional external validation results based on multiple databases.

**References**

[1] N. Tsoukalas, E. Aravantinou-Fatorou, P. Baxevanos et al., “Advanced small cell lung cancer (SCLC): new challenges and new expectations,” *Annals of Translational Medicine*, vol. 6, no. 8, p. 145, 2018.

[2] X. Zhao, B. Kallakury, J. J. Chahine et al., “Surgical resection of SCLC: prognostic factors and the tumor microenvironment,” *Journal of Thoracic Oncology*, vol. 14, no. 5, pp. 914–923, 2019.

[3] S. Yang, Z. Zhang, and Q. Wang, “Emerging therapies for small cell lung cancer,” *Journal of Hematology & Oncology*, vol. 12, no. 1, p. 47, 2019.

[4] N. Xenidis, A. Kotsakis, A. Kalykaki et al., “Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small
cell lung cancer: a multicenter phase II study," Lung Cancer, vol. 68, no. 3, pp. 450–454, 2010.

[5] P. Sunpaweravong, L. Magree, R. Rabinovitch, P. Bunn, and K. Kelly, "A phase II/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer," Investigational New Drugs, vol. 24, no. 3, pp. 213–221, 2006.

[6] K. Kubota, T. Hida, S. Ishikura et al., "Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study," The Lancet Oncology, vol. 15, no. 1, pp. 106–113, 2014.

[7] J. R. Eckardt, J. von Pawel, J.-L. Pujol et al., "Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer," Journal of Clinical Oncology, vol. 25, no. 15, pp. 2086–2092, 2007.

[8] N. Masuda, K. Matsui, S. Negoro et al., "Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer," Journal of Clinical Oncology, vol. 16, no. 10, pp. 3329–3334, 1998.

[9] C. M. Rocha-Lima, J. E. Herndon, M. E. Lee et al., "Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: cancer and Leukemia Group B Study 39902," Annals of Oncology, vol. 18, no. 2, pp. 331–337, 2007.

[10] Y. Misumi, H. Okamoto, J. Sasaki et al., "Phase II/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604," BMC Cancer, vol. 17, no. 1, p. 377, 2017.

[11] T. K. Owonikoko, S. E. Dahlberg, G. L. Sica et al., "Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study," Journal of Clinical Oncology, vol. 37, no. 3, pp. 222–229, 2019.

[12] E. S. Kim, "Chemotherapy resistance in lung cancer," Lung Cancer and Personalized Medicine, vol. 893, pp. 189–209, 2016.

[13] P. Chen, P. Kuang, L. Wang et al., "Mechanisms of drug-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure," Translational Lung Cancer Research, vol. 9, no. 3, pp. 768–786, 2020.

[14] R. Y. Tay, F. Fernández-Gutiérrez, V. Foy et al., "Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial," Annals of Oncology, vol. 30, no. 7, pp. 1114–1120, 2019.

[15] R. Van Den Borg, A. Leonetti, M. Tiseo, E. Giovannetti, and G. J. Peters, "Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and ralitpuzumab tesirine," Expert Review of Anticancer Therapy, vol. 19, no. 6, pp. 461–471, 2019.

[16] A. E. McKee and P. A. Silver, "Systems perspectives on mRNA processing," Cell Research, vol. 17, no. 7, pp. 581–590, 2007.

[17] M. Shimomura, T. Yaoi, K. Itou et al., "Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines," International Journal of Oncology, vol. 40, no. 4, pp. 995–1004, 2012.

[18] Y. Xiao, C. Yin, Y. Wang et al., "FBXW 7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy," Molecular oncology, vol. 12, no. 6, pp. 883–895, 2018.

[19] P. Kuang, P. Chen, L. Wang et al., "RNA sequencing analysis of small cell lung cancer reveals candidate chemotherapy insensitivity long noncoding RNAs and microRNAs," Annals of Translational Medicine, vol. 8, no. 4, p. 121, 2020.
associations between proteins,” Nucleic Acids Research, vol. 31, no. 1, pp. 258–261, 2003.
[37] “KEGG Pathway database,” Available from: https://www.genome.jp/kegg/pathway.html.
[38] “Pathway card,” Available from: https://pathcards.genecards.org/.
[39] I. K. Demeds, K. Y. Vermaelen, and J. P. van Meerbeeck, “Treatment of extensive-stage small cell lung carcinoma: current status and future prospects,” European Respiratory Journal, vol. 35, no. 1, pp. 202–215, 2010.
[40] M. Reck, A. Luft, A. Szczesna et al., “Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer,” Journal of Clinical Oncology, vol. 34, no. 31, pp. 3740–3748, 2016.
[41] H. Okamoto, K. Watanabe, K. Watanabe et al., “Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702,” British Journal of Cancer, vol. 97, no. 2, pp. 162–169, 2007.
[42] V. Noronha, A. Sahu, V. M. Patil et al., “Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer,” South Asian Journal of Cancer, vol. 5, no. 2, pp. 067–069, 2016.
[43] J. Zhou, Z. Li, J. Li, B. Gao, and W. Song, “Chemotherapy resistance molecular mechanism in small cell lung cancer,” Current Molecular Medicine, vol. 19, no. 3, pp. 157–163, 2019.
[44] Y. Canitrot, F. Bichat, S. P. C. Cole et al., “Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer,” Cancer Letters, vol. 130, no. 1–2, pp. 133–141, 1998.
[45] K. Berns and A. Berns, “Awakening of "Schlafen11" to tackle chemotherapy resistance in SCLC,” Cancer Cell, vol. 31, no. 2, pp. 169–171, 2017.
[46] O. Stegle, S. A. Teichmann, and J. C. Marioni, “Computational and analytical challenges in single-cell transcriptomics,” Nature Reviews Genetics, vol. 16, no. 3, pp. 133–145, 2015.
[47] M. Matsumoto, M. Seike, R. Noro et al., “Control of the MYC-Elf4E axis plus mTOR inhibitor treatment in small cell lung cancer,” BMC Cancer, vol. 15, no. 1, p. 241, 2015.
[48] H. Tang, J. Chen, X. Han, Y. Feng, and F. Wang, “Upregulation of SPPI as a marker for poor lung cancer prognosis and contributes to cancer progression and cisplatin resistance,” Frontiers in cell and developmental biology, vol. 9, Article ID 646390, 2021.
[49] C. L. Che, Y. M. Zhang, H. H. Zhang et al., “DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line,” International Journal of Clinical and Experimental Pathology, vol. 6, pp. 1538–1548, 2013.
[50] Z. G. Leng, S. J. Lin, Z. R. Wu et al., “Activation of DR5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death,” Autophagy, vol. 13, no. 8, pp. 1404–1419, 2017.
[51] S. Thongprasert, P.-C. Yang, J. S. Lee et al., “The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients,” Lung Cancer, vol. 101, pp. 137–144, 2016.
[52] J. Bankovic, J. Stojisic, D. Jovanovic et al., “Identification of genes associated with non-small-cell lung cancer promotion and progression,” Lung Cancer, vol. 67, no. 2, pp. 151–159, 2010.
[53] Q. Huang, H. Wei, Z. Wu et al., “ Preferentially expressed antigen of melanoma prevents lung cancer metastasis,” PLoS One, vol. 11, no. 7, Article ID e0149640, 2016.
[54] W. Zhang, L. Li, L. Cai et al., “Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2Prame complex,” Cell Death & Differentiation, vol. 28, no. 6, pp. 1926–1940, published online EpubJun, 2021.
[55] M. Albertsmeier, A. Altendorf-Hofmann, L. H. Lindner et al., “Cancer testis antigens and immunotherapy: expression of PRAME is associated with prognosis in soft tissue sarcoma,”Cancers, vol. 12, no. 12, p. 3612, 2020.
[56] S. Peng, T. Du, W. Wu et al., “Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression,” Urologic Oncology: Seminars and Original Investigations, vol. 36, no. 8, pp. 366.e1–366.e369, 2018.
[57] A. Heddar, P. Dessen, D. Flatters, and M. Misrahi, “Novel STAG3 mutations in a caucasian family with primary ovarian insufficiency,” Molecular Genetics and Genomics, vol. 294, no. 6, pp. 1527–1534, 2019.
[58] C.-H. Shen, S. H. Kim, S. Trousl et al., “Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma,” Nature Medicine, vol. 22, no. 9, pp. 1056–1061, 2016.
[59] M. Sorokin, E. Podubskaya, M. Baranova et al., “RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer,” Molecular Case Studies, vol. 6, no. 2, Article ID a004945, 2020.
[60] J. Ding and Y. Zhang, “Analysis of key GO terms and KEGG pathways associated with carcinogenic chemicals,” Combinatorial Chemistry & High Throughput Screening, vol. 20, no. 10, pp. 861–871, 2018.
[61] T. Herjan, L. Hong, J. Bubenik et al., “IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling,” Nature Immunology, vol. 19, no. 4, pp. 354–365, 2018.
[62] B. Tessier-Cloutier, A. E. Clarke, R. Ramsey-Goldman, C. Gordon, J. E. Hansen, and S. Bernatsky, “Systemic lupus erythematosus and malignancies,” Rheumatic Disease Clinics of North America, vol. 40, no. 3, pp. 497–506, 2014.
[63] D. Hardenbergh, R. Naik, R. Mannio et al., “The cancer risk profile of systemic lupus erythematosus patients,” Journal of Clinical Rheumatology, 2021.
[64] H. Peng, C. Li, X. Wu et al., “Association between systemic lupus erythematosus and lung cancer: results from a pool of cohort studies and Mendelian randomization analysis,” Journal of Thoracic Disease, vol. 12, no. 10, pp. 5299–5312, 2020.
[65] A. A. Shah, T. Igusa, D. Goldman et al., “Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection,” Arthritis Research and Therapy, vol. 23, no. 1, pp. 19, 2021.
[66] A. A. Shah, T. Igusa, D. Goldman et al., “Gene-set meta-analysis of lung cancer identifies pathway related to systemic lupus erythematosus,” PloS One, vol. 12, no. 3, Article ID e0173339, 2017.
[67] L. Su, S. Cui, H. Zhen, and J. Liu, “Quantitative proteomic study of mitoxantrone-resistant NCI-H460 cell-xenograft tumors,” International Journal of Clinical and Experimental Pathology, vol. 12, no. 9, pp. 2377–2388, 2018.
[68] H.-S. Han, G. Kang, J. S. Kim, B. H. Choi, and S.-H. Koo, “Regulation of glucose metabolism from a liver-centric perspective,” Experimental & Molecular Medicine, vol. 48, no. 3, pp. e218, 2016.
[69] R. Ma, Y. Wu, S. Li, and X. Yu, “Interplay between glucose metabolism and chromatin modifications in cancer,” *Frontiers in cell and developmental biology*, vol. 9, Article ID 654337, 2021.

[70] B. A. Teicher, “Targets in small cell lung cancer,” *Biochemical Pharmacology*, vol. 87, no. 2, pp. 211–219, 2014.

[71] K. Nie, Y. X. Zhang, W. Nie et al., “Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: a systematic review and meta-analysis,” *Journal of Medical Imaging and Radiation Oncology*, vol. 63, no. 1, pp. 84–93, 2019.

[72] Q. Duan, D. Li, L. Xiong, Z. Chang, and G. Xu, “SILAC quantitative proteomics and biochemical analyses reveal a novel molecular mechanism by which ADAM12S promotes the proliferation, migration, and invasion of small cell lung cancer cells through upregulating hexokinase 1,” *Journal of Proteome Research*, vol. 18, no. 7, pp. 2903–2914, 2019.

[73] A. Banerjee, P. Arvinrad, M. Darley et al., “The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells,” *Oncotarget*, vol. 9, no. 33, pp. 23274–23288, 2018.

[74] R. Polański, C. L. Hodgkinson, A. Fusi et al., “Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer,” *Clinical Cancer Research*, vol. 20, no. 4, pp. 926–937, 2014.

[75] A. Deshmukh, K. Deshpande, F. Arfuso, P. Newsholme, and A. Dharmarajan, “Cancer stem cell metabolism: a potential target for cancer therapy,” *Molecular Cancer*, vol. 15, no. 1, p. 69, 2016.

[76] Z. Ghanbari Movahed, M. Rastegari-Pouyani, M. H. Mohammadi, and K. Mansouri, “Cancer cells change their glucose metabolism to overcome increased ROS: one step from cancer cell to cancer stem cell?” *Biomedicine & Pharmacotherapy*, vol. 112, Article ID 108690, 2019.

[77] C. Cheng, Z. Xie, Y. Li, J. Wang, C. Qin, and Y. Zhang, “PTBP1 knockdown overcomes the resistance to vincristine and oxaliplatin in drug-resistant colon cancer cells through regulation of glycolysis,” *Biomedicine & Pharmacotherapy*, vol. 108, pp. 194–200, 2018.

[78] Y. Dai, F. Li, Y. Jiao et al., “Mortalin/glucose-regulated protein 75 promotes the cisplatin-resistance of gastric cancer via regulating anti-oxidation/apoptosis and metabolic reprogramming,” *Cell Death Discovery*, vol. 7, no. 1, p. 140, 2021.

[79] M. Feng, G. Xiong, Z. Cao et al., “LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer,” *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, p. 274, 2018.

[80] M. Xu, S. Chen, W. Yang et al., “FGFR4 links glucose metabolism and chemotherapy resistance in breast cancer,” *Cellular Physiology and Biochemistry*, vol. 47, no. 1, pp. 151–160, 2018.

[81] M. Apicella, E. Giannoni, S. Fiore et al., “Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies,” *Cell Metabolism*, vol. 28, no. 6, pp. 848–865, 2018.